Products
OMCAZIO™ (cabozantinib)
An FDA-approved kinase inhibitor for advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) previously treated with sorafenib, and previously treated extra-pancreatic neuroendocrine tumors (epNET) in adults and pediatric patients 12 years and older. Administered once daily, with or without food. As a laurylsulfate salt formulation, OMCAZIO is available in lower milligram-strengths (34.5 mg, 23 mg, and 11.5 mg) that correspond to approved CABOMETYX® doses and is not substitutable on a mg-to-mg basis with other cabozantinib products. OMCAZIO is a trademark of Handa Oncology, LLC.
PHYRAGO™ (dasatinib)
An FDA-approved kinase inhibitor for Philadelphia chromosome-positive (Ph+) leukemias (CML and Ph+ ALL) in adults and pediatric patients 1 year and older. Administered once daily, with or without food. Unlike with antacids, no clinically significant pharmacokinetic effect was observed when PHYRAGO was taken with PPIs or H2-receptor antagonists. PHYRAGO is a trademark of Handa Therapeutics, LLC.
TASCENSO ODT® (fingolimod)
An FDA-approved orally disintegrating tablet (0.25 mg, 0.5 mg) for relapsing forms of multiple sclerosis in patients 10 years and older. Built on Zydis ODT technology (Catalent), it dissolves on the tongue with or without water — a patient-friendly option for those with swallowing difficulties. TASCENSO ODT is a trademark of Handa Neuroscience, LLC.